Cargando…
Abnormal peripheral chemokine profile in Huntington’s disease
Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by both neurological and systemic abnormalities. Immune activation is a well-established feature of the HD brain and we have previously demonstrated a widespread, progressive innate immune response detectable in plasm...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082446/ https://www.ncbi.nlm.nih.gov/pubmed/21826115 http://dx.doi.org/10.1371/currents.RRN1231 |
_version_ | 1782202289407131648 |
---|---|
author | Wild, Edward Magnusson, Anna Lahiri, Nayana Krus, Ulrika Orth, Michael Tabrizi, Sarah J Björkqvist, Maria |
author_facet | Wild, Edward Magnusson, Anna Lahiri, Nayana Krus, Ulrika Orth, Michael Tabrizi, Sarah J Björkqvist, Maria |
author_sort | Wild, Edward |
collection | PubMed |
description | Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by both neurological and systemic abnormalities. Immune activation is a well-established feature of the HD brain and we have previously demonstrated a widespread, progressive innate immune response detectable in plasma throughout the course of HD. In the present work we used multiplex ELISA to quantify levels of chemokines in plasma from controls and subjects at different stages of HD. We found an altered chemokine profile tracking with disease progression, with significant elevations of five chemokines (eotaxin-3, MIP-1β, eotaxin, MCP-1 and MCP-4) while three (eotaxin-3, MIP-1β and eotaxin) showed significant linear increases across advancing disease stages. We validated our results in a separate sample cohort including subjects at different stages of HD. Here we saw that chemokine levels (MCP-1 and eotaxin) correlated with clinical scores. We conclude that, like cytokines, chemokines may be linked to the pathogenesis of HD, and that immune molecules may be valuable in tracking and exploring the pathogenesis of HD. |
format | Text |
id | pubmed-3082446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30824462011-08-04 Abnormal peripheral chemokine profile in Huntington’s disease Wild, Edward Magnusson, Anna Lahiri, Nayana Krus, Ulrika Orth, Michael Tabrizi, Sarah J Björkqvist, Maria PLoS Curr Huntington Disease Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by both neurological and systemic abnormalities. Immune activation is a well-established feature of the HD brain and we have previously demonstrated a widespread, progressive innate immune response detectable in plasma throughout the course of HD. In the present work we used multiplex ELISA to quantify levels of chemokines in plasma from controls and subjects at different stages of HD. We found an altered chemokine profile tracking with disease progression, with significant elevations of five chemokines (eotaxin-3, MIP-1β, eotaxin, MCP-1 and MCP-4) while three (eotaxin-3, MIP-1β and eotaxin) showed significant linear increases across advancing disease stages. We validated our results in a separate sample cohort including subjects at different stages of HD. Here we saw that chemokine levels (MCP-1 and eotaxin) correlated with clinical scores. We conclude that, like cytokines, chemokines may be linked to the pathogenesis of HD, and that immune molecules may be valuable in tracking and exploring the pathogenesis of HD. Public Library of Science 2011-04-13 /pmc/articles/PMC3082446/ /pubmed/21826115 http://dx.doi.org/10.1371/currents.RRN1231 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Huntington Disease Wild, Edward Magnusson, Anna Lahiri, Nayana Krus, Ulrika Orth, Michael Tabrizi, Sarah J Björkqvist, Maria Abnormal peripheral chemokine profile in Huntington’s disease |
title | Abnormal peripheral chemokine profile in Huntington’s disease |
title_full | Abnormal peripheral chemokine profile in Huntington’s disease |
title_fullStr | Abnormal peripheral chemokine profile in Huntington’s disease |
title_full_unstemmed | Abnormal peripheral chemokine profile in Huntington’s disease |
title_short | Abnormal peripheral chemokine profile in Huntington’s disease |
title_sort | abnormal peripheral chemokine profile in huntington’s disease |
topic | Huntington Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082446/ https://www.ncbi.nlm.nih.gov/pubmed/21826115 http://dx.doi.org/10.1371/currents.RRN1231 |
work_keys_str_mv | AT wildedward abnormalperipheralchemokineprofileinhuntingtonsdisease AT magnussonanna abnormalperipheralchemokineprofileinhuntingtonsdisease AT lahirinayana abnormalperipheralchemokineprofileinhuntingtonsdisease AT krusulrika abnormalperipheralchemokineprofileinhuntingtonsdisease AT orthmichael abnormalperipheralchemokineprofileinhuntingtonsdisease AT tabrizisarahj abnormalperipheralchemokineprofileinhuntingtonsdisease AT bjorkqvistmaria abnormalperipheralchemokineprofileinhuntingtonsdisease |